Last reviewed · How we verify
PN20
At a glance
| Generic name | PN20 |
|---|---|
| Also known as | thrombopoietin receptor agonist |
| Sponsor | Chongqing Peg-Bio Biopharm Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Safety and Efficacy of PN20 in the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure (PHASE1, PHASE2)
- Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP) (PHASE1)
- A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor Patients (PHASE1)
- Efficacy and Safety of PN20 (Plinest) for the Improvement of Skin Hydration (NA)
- A Study of PN20 in Healthy Adult Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PN20 CI brief — competitive landscape report
- PN20 updates RSS · CI watch RSS
- Chongqing Peg-Bio Biopharm Co., Ltd. portfolio CI